The effects of adjuvant hormonotherapy on tear functions in patients with breast cancer


Bicer T., Imamoglu G. I., Dogan A. S., Avarisli N. A., Kabatas N., KÜÇÜK BİÇER B., ...Daha Fazla

INTERNATIONAL OPHTHALMOLOGY, cilt.40, sa.8, ss.2077-2083, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 40 Sayı: 8
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1007/s10792-020-01384-7
  • Dergi Adı: INTERNATIONAL OPHTHALMOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Agricultural & Environmental Science Database, BIOSIS, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.2077-2083
  • Anahtar Kelimeler: Aromatase inhibitors, Breakup time, Dry eye syndrome, OSDI, Schirmer test, Tamoxifen, DRY EYE SYNDROME, ESTROGEN-RECEPTOR, AROMATASE INHIBITOR, ENDOCRINE THERAPY, SJOGRENS-SYNDROME, SEX-HORMONES, TAMOXIFEN, EXPRESSION, GLANDS, WOMEN
  • Gazi Üniversitesi Adresli: Evet

Özet

Purpose Aromatase inhibitors (anastrozole, letrozole) and selective estrogen receptor modulators (tamoxifen) are widely used as adjuvant hormonal therapy in women with hormone receptor-positive breast cancer. We aimed to evaluate the effects of oral adjuvant hormonotherapy on tear functions in patients with breast cancer. Methods In this case-control study, we enrolled eligible patients with breast cancer who were receiving regular medical selective estrogen receptor modulator (tamoxifen, n:50), aromatase inhibitors (anastrozole, letrozole, n:50) and gender-matched healthy controls (n:50). Tear functions were measured and compared by the Schirmer test, fluorescein breakup time, corneal staining evaluated by Oxford grading scale and Ocular Surface Disease Index scores. Results Mean age was 49.95 (+/- 9.2), 51.52 (+/- 7.2) and 51.91 (+/- 10.3) in tamoxifen, aromatase inhibitors groups and controls (p = 0.426). Mean duration of BC diagnosis (p = 0.536) and drug use (p = 0.417) was not significant between two groups. Ocular Surface Disease Index scores were lower (p < 0.001), and fluorescein breakup time measurements were higher (p < 0.001) in controls. Schirmer test scores were higher in controls than aromatase inhibitors group (p < 0.001). According to the scores of all measurements, the differences between aromatase inhibitors and tamoxifen groups were statistically significant (p < 0.001). Conclusions Our results demonstrated a high difference in all parameters in patients receiving aromatase inhibitors compared to tamoxifen group and controls. Aromatase inhibitors, which reduce estrogen levels in the blood, might affect the tear functions more than tamoxifen, which affects as antiestrogenic on estrogen receptors.